CytomX Therapeutics Announces Changes to its Board of Directors
- President and CEO Sean McCarthy, D. Phil., Appointed to Additional Role of Chairman -
- Hoyoung Huh, M.D., Ph.D. Retiring from Board -
- James R. Meyers, Former EVP at
Hoyoung Huh, M.D., Ph.D., who has served as chairman of CytomX’s board of directors since
“On behalf of CytomX’s management and Board, I would like to thank Hoyoung for his strategic leadership and insight over the last six years,” said Sean McCarthy, D.Phil., president and chief executive officer of CytomX. “Hoyoung has helped us mature CytomX from an early stage startup company to an integrated research and development organization with multiple wholly-owned and partnered product candidates in the clinic. I am delighted that CytomX will continue to benefit from his expertise as an advisor as we continue to advance towards realizing our vision of transforming lives with safer, more effective therapies.”
In conjunction with Dr. McCarthy’s appointment as chairman, existing company director Matthew Young has been appointed to the role of lead independent director.
The company also announced that James R. Meyers has been appointed as an independent director to the CytomX board.
Mr. Meyers brings more than 30 years of worldwide commercial leadership experience within the biotechnology industry. Mr. Meyers has served as a senior advisor to
Continued Dr. McCarthy, “We are honored to have Jim joining our Board of Directors as we continue to advance our clinical stage pipeline and drive towards building a commercial-stage organization. Jim brings deep operational and strategic expertise and is a recognized leader with a proven track record of commercial success. I look forward to working closely with Jim and the full board as we endeavor to take CytomX to the next level.”
Commenting on his appointment Mr. Meyers said, “I’m thrilled to be joining the CytomX board at this pivotal time in the company’s evolution and I very much look forward to contributing to the further advancement of this unique organization.”
CytomX Therapeutics Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements. Accordingly, you should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety and efficacy of CytomX’s or any of its collaborative partners’ product candidates and CytomX’s ability and the ability of its collaborative partners to develop and advance product candidates into and successfully complete clinical trials. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: three of CytomX’s product candidates under its Probody platform are in the initial stages of clinical development and its other product candidates are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties. Additional applicable risks and uncertainties include those relating to our preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in CytomX’s Quarterly Report on Form 10-Q filed with the
Investors and Media:
Chief Financial Officer
VP, Investor Relations and Corporate Communications
Source: CytomX Therapeutics Inc.